Fox Chase Cancer Center Breast Program Receives Re-Accreditation

“This completely flies in the face of what we have always assumed,” Bleicher said. “There are very good reasons to give chemotherapy before surgery in each of these phenotypes of breast cancer that have nothing to do with treatment times. But while preoperative chemotherapy is sometimes advocated solely to rush the start of treatment faster than surgery, unless delays are anticipated, these data tell us that switching the order of treatment specifically for this reason is not likely to help these pati


PHILADELPHIA (January 17, 2023)—Fox Chase Cancer Center has successfully renewed its accreditation with the National Accreditation Program for Breast Centers (NAPBC), making it the fifth consecutive time Fox Chase has received accreditation.

The NAPBC, which is one of the Quality Programs of the American College of Surgeons, is the premier accreditation program for breast centers in the United States. The standards set forth by the NAPBC represent the entire cancer care continuum from prevention through survivorship and end-of-life care.

“This is external validation that the quality of breast care at Fox Chase Cancer Center is among the best not just in any particular area but for patients having benign disease, as well as through all aspects of breast cancer care from screening and diagnosis all the way to survivorship,” said Richard Bleicher, MD, FACS, professor in the Department of Surgical Oncology and leader of the Breast Cancer Program at Fox Chase.

Through NAPBC accreditation, organizations are able to assure patients that they are receiving the best quality care.

Their standards span across disciplines to effectively evaluate overall breast disease and cancer care. The standards touch on areas such as access to information, a multidisciplinary team approach, ongoing improvement of care, and information about clinical trials and new treatment options.

“We appreciate that this has been recognized by the American College of Surgeons and are very grateful to be in this position to be able to help women who are faced with both benign breast disease as well as the burden of cancer,” said Bleicher.

Every three years, breast centers must apply for reaccreditation, which measures performance based on the current NAPBC Standards Manual.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427